This review summarises and discusses the long-term follow-up of alemtuzumab-treated patients with active
relapsing-remitting multiple sclerosis (RRMS) and an inadequate response to prior therapy who were enrolled
in the 2-year Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) II study.1
Data from the 4-year extension study of CARE-MS II, and the first 2 years of the subsequent 5-year long-Term
follow-up study for multiple sclerOsis Patients who have completed the AlemtuZumab extension study (TOPAZ),
were presented at the AAN and ECTRIMS international scientific meetings in 2018.2,3,4,5 Alemtuzumab showed durable clinical efficacy and a consistent safety profile through year 8 in patients with active RRMS.5 Disease control was also maintained over a 3-year period in patients who received alemtuzumab retreatment due to disease activity after the initial 2 courses.4
Independent expert commentary provided by Dr Mike Boggild from North Queensland.
Please login below to download this issue (PDF)